Sotatercept-Csrk
Last Updated: 02/24/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 7 publications
Pharmacovigilance Analysis of Sotatercept for the Treatment of Pulmonary Arterial Hypertension Based on FAERS Database.
Journal: Cardiovascular toxicology
Published: October 04, 2025
Sotatercept: A First-In-Class Activin Signaling Inhibitor for Pulmonary Arterial Hypertension.
Journal: The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians
Published: February 25, 2025
The Drug Update: Recent drug approvals, winter 2025 edition.
Journal: The Nurse practitioner
Published: January 23, 2025
Sotatercept: The First FDA-Approved Activin A Receptor IIA Inhibitor Used in the Management of Pulmonary Arterial Hypertension.
Journal: American journal of cardiovascular drugs : drugs, devices, and other interventions
Published: October 15, 2024
Sotatercept: New drug on the horizon of pulmonary hypertension.
Journal: Vascular pharmacology
Published: October 10, 2024
Sotatercept (Winrevair) for pulmonary arterial hypertension.
Journal: The Medical letter on drugs and therapeutics
Published: May 02, 2024
Showing 1-7 of 7
Last Updated: 02/24/2026